Portal:CPTAC
From WikiPathways
Current revision (09:21, 6 October 2019) (view source) |
|||
| (3 intermediate revisions not shown.) | |||
| Line 9: | Line 9: | ||
}} | }} | ||
| - | <div style="float:left; width: | + | <div style="float:left; width:73%"> <!-- This width add to the the margin below to equal 99% --> |
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 23: | Line 23: | ||
</div> | </div> | ||
| - | <div style="float:right; width: | + | <div style="float:right; width:26%"> <!-- This margin should be right of the above --> |
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 33: | Line 33: | ||
{{FULLPAGENAME}}/Featured | {{FULLPAGENAME}}/Featured | ||
|<!-- FOOTER LINK --> | |<!-- FOOTER LINK --> | ||
| + | }} | ||
| + | |||
| + | {{{{FULLPAGENAME}}/box-normal | ||
| + | |<!-- TITLE OF BOX --> | ||
| + | <big>''Assay Portal''</big> | ||
| + | |<!-- EDIT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | |<!-- CONTENT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | | | ||
}} | }} | ||
| Line 55: | Line 65: | ||
}} | }} | ||
</div> | </div> | ||
| + | |||
| + | [[Category:Portals]] | ||
Current revision
CPTAC Pathways
Welcome to the CPTAC Pathway PortalThis portal highlights pathway content relevant to the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The National Cancer Institute, part of the National Institutes of Health, announced the launch of a Clinical Proteomic Tumor Analysis Consortium in August 2011. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer. To achieve this goal in a scientifically rigorous manner, the NCI launched CPTAC to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public. The pathways included in this portal have been organized into classic cancer hallmark categories, based on the different biological capabilities acquired during the multistep development of human tumors. To read more, see Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011. | 
|
Cancer Hallmark Categories
| Sustaining proliferative signaling
Ras signaling (Homo sapiens) Image does not exist Ras signaling | Evading growth suppressors
TGF-beta receptor signaling (Homo sapiens) Image does not exist TGF-beta receptor signaling | Activating invasion and metastasis
TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition (Homo sapiens) Image does not exist TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition |
| Enabling replicative immortality
ncRNAs in Wnt signaling in hepatocellular carcinoma (Homo sapiens) Image does not exist ncRNAs in Wnt signaling in hepatocellular carcinoma | Inducing angiogenesis
VEGFA-VEGFR2 signaling (Homo sapiens) Image does not exist VEGFA-VEGFR2 signaling | Resisting cell death
TP53 network (Homo sapiens) Image does not exist TP53 network |
| Deregulating cellular energetics
Hereditary leiomyomatosis and renal cell carcinoma pathway (Homo sapiens) Image does not exist Hereditary leiomyomatosis and renal cell carcinoma pathway | Genome instability and mutation
Chromosomal and microsatellite instability in colorectal cancer (Homo sapiens) Image does not exist Chromosomal and microsatellite instability in colorectal cancer | Tumor promoting inflammation
Chemokine signaling (Homo sapiens) Image does not exist Chemokine signaling |
| Avoiding immune destruction
Type II interferon signaling (Homo sapiens) Image does not exist Type II interferon signaling | Therapeutics
lncRNA-mediated mechanisms of therapeutic resistance (Homo sapiens) Image does not exist lncRNA-mediated mechanisms of therapeutic resistance |
Featured Pathways
|
Image does not exist PDGFR-beta pathway Zhang, et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer |
| View featured pathways |
| List of all pathways for this portal |
Assay Portal
CPTAC also includes an Assay Portal to widely disseminate highly characterized proteomic assays to the global research community, with access to SOPs, reagents, and assay characterization/validation data
Resources
- Over 2400 protein and peptide assays: Browse assays
- Over 750 antibodies and antigen targets: Browse antibodies
- Hundreds of terabytes of data sets: Browse data
Learn how they incorpated WikiPathways images with custom links on their site.
Pathway Curation
On this page you see rotating displays of hallmark and featured pathways. Where did these pathways come from? They came from people like you! The CPTAC set of pathways can be edited, fixed and added to using the pathway drawing and annotation tools here at WikiPathways.
Getting Started
- Introduction to WikiPathways (slides)
- WikiPathways Overview or New Contributor Quickstart
- General help pages
- CPTAC Workshop Exercises
Resources
- Learn more about CPTAC
- Pathway analysis
- Cytoscape and the WikiPathways app
- PathVisio and the WikiPathways plugin
Curation projects
- Curating Hallmark Pathways -- How to
- Example: construction of Pathways in Renal Cancer
- Contact Alex Pico if interested in curating, adding or using CPTAC pathways, apico@gladstone.ucsf.edu
